The monthly injectable regimen comprising the INSTI* cabotegravir and the NNRTI** rilpivirine long-acting (CAB+RPV LA) maintained virological suppression (ie, plasma HIV-1 RNA <50 copies/mL) in almost all participants of the phase III ATLAS*** trial who entered the extension phase, according to the 96-week analysis presented at HIV Glasgow 2020.
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.
Switching to a single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) maintains virologic suppression over 72 weeks in older people living with HIV (PLWH), according to a study presented at the HIV Glasgow 2020 Congress.
An oral lead-in (OLI) regimen consisting of cabotegravir + rilpivirine (CAB+RPV) did not seem to have an effect on HIV patients who switched from a daily oral dolutegravir/abacavir/lamivudine (ABC/DTG/3TC) regimen to a monthly injectable CAB+RPV long-acting (LA) therapeutic regimen, given the similar efficacy, safety, and tolerability profiles observed with or without OLI, according to the 124-week results of the phase III FLAIR* trial presented at HIV Glasgow 2020.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.